Disease/Infection News

RSS

Researchers examine the effectiveness of the Pfizer-BioNTech COVID-19 vaccine in reducing household transmission

A new study has been published on the medRxiv* preprint server, which focuses on the effectiveness of the BNT162b2 vaccine by studying the susceptibility of a vaccinated individual to infection. The researchers have also studied the effect of the vaccine on virus transmission.

20 Jul 2021

Study examines clinical outcomes in vaccinated individuals hospitalized with SARS-CoV-2 Delta variant

A new study has been published on the medRxiv* preprint server that has evaluated the clinical outcomes of the COVID-19 patients hospitalized in AIG hospitals, Hyderabad, India, between April 24, 2021, and May 31, 2021.

20 Jul 2021

Study reports on COVID-19 vaccine uptake and antibody prevalence in England during May 2021

A new study reports this finding, along with varying antibody prevalence among different groups and regions and between different age groups. In the current paper, available as a preprint on the medRxiv* server, the results of the sixth round of the REACT-2 study are reported.

20 Jul 2021

Study suggests COVID-19 vaccine confidence and hesitancy in the UK driven by trust, not misinformation

An interesting new study reports that vaccine hesitancy in the UK is driven not, as is commonly thought, by the so-called ‘infodemic’ of misinformation that has characterized much public messaging during the COVID-19 pandemic. Instead, the personality of the individual, the ability to trust scientific and government leadership, political affiliations, and openness relative to the process of vaccine development was found to be key in the development of this attitude.

20 Jul 2021

COVID-19 vaccination in New York City reduces hospital admissions and deaths

A new study, released as a preprint on the medRxiv* server, shows how the successful rollout of effective COVID-19 vaccines in this metropolis led to the dramatic reduction in the number of cases with moderate to severe coronavirus disease 2019 (COVID-19) and curbed COVID-19-related mortality.

20 Jul 2021

NIH grant supports WVU-led team to increase COVID-19 testing among underserved populations

Not all West Virginians have the luxury of popping into a health clinic on a whim to get tested for COVID-19.

20 Jul 2021

Owlstone Medical publishes data on the use of face mask filters to capture viral particles for SARS-CoV-2 detection

Owlstone Medical today announced the publication of a peer-reviewed study in Nature Scientific Reports.

From Owlstone Medical Ltd 20 Jul 2021

Yeast expressed, RBD-based vaccine provides robust immune responses against SARS-CoV-2

The ongoing coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 190 million cases worldwide. Of these, over 4 million have died due to the infection.

20 Jul 2021

Redhill Biopharma announces completion of Phase 2/3 COVID-19 study of oral opaganib

RedHill Biopharma Ltd., a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840). Top-line results are expected in the coming weeks.

20 Jul 2021

How SARS-CoV-2 infects the brain

While there is no official explanation on how SARS-CoV-2 travels to the brain, a new review published in the journal Fluids and Barriers of the CNS concluded that there is insufficient evidence on COVID-induced neurological problems coming from a direct invasion of SARS-CoV-2 into the brain.

20 Jul 2021

Exhausted T cells linked to increased risk of COVID-19 mortality

New research led by Nadia R. Roan of Gladstone Institutes and the University of California, San Francisco, finds a correlation between high numbers of inflammatory CXCR4+ T cells and regulatory T cells specific to SARS-CoV-2 and dying from infection. In contrast, people who recovered from severe COVID-19 illness were more likely to have many SARS-CoV-2-specific T cells that perform homeostatic proliferation.

20 Jul 2021

Study proves effectiveness of Artemisia annua against SARS-CoV-2 in vitro

A multinational research group has been the first to show the excellent activity of artemisinin-based treatment against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human cell lines – including a specific type of lung cells. Their findings were recently published in the journal Scientific Reports.

19 Jul 2021

Past SARS-CoV-2 infection enhances mRNA vaccine-induced neutralization of variants of concern

Researchers in the United States have conducted a study suggesting that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit better neutralizing activity against variants of concern following vaccination against coronavirus disease 2019 (COVID-19) than previously uninfected vaccinees.

19 Jul 2021

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Researchers in Finland have conducted a study showing that the neutralizing bodies generated following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – generally persist for at least a year.

19 Jul 2021

Iodine derivative kills SARS-CoV-2 within 90 sec

A recent study estimated the virucidal efficacy of EID for oral/nasal decontamination of known or suspected cases of COVID-19.

19 Jul 2021

Researchers develop new tool to simulate the impact of SARS-CoV-2 strains and vaccines

The MOMAT research group from Universidad Complutense de Madrid has worked with Universidad de Almería, to develop a mathematical model that simulates the impact of SARS-CoV-2 strains and vaccines together, combined with many other biological and social processes in the propagation of COVID-19.

19 Jul 2021

Thai study looks at CoronaVac vaccine vs. natural immunity to SARS-COV-2 variants

A new study evaluates the efficacy of vaccine- and infection-induced antibodies against SARS-CoV-2 variants.

19 Jul 2021

Antibody levels remain high nine months after SARS-CoV-2 infection, study shows

Testing of an entire Italian town shows antibody levels remain high nine months after SARS-CoV-2 infection, whether symptomatic or asymptomatic.

19 Jul 2021

Functional autoantibody in COVID-19 contributes to the 'firestorm' of blood clots and inflammation

Researchers at Michigan Medicine have discovered yet another functional autoantibody in COVID-19 patients that contributes to the disease's development and the "firestorm" of blood clots and inflammation it induces.

19 Jul 2021

New project receives NIHR funding to develop personalized rehabilitation program for long Covid patients

A new research project, led by a team from St George's, University of London and Kingston University as well as Cardiff University, has received major funding from the National Institute for Health Research to develop personalized rehabilitation programmes to help patients live well with long Covid.

19 Jul 2021

Disease/Infection News

Researchers examine the effectiveness of the Pfizer-BioNTech COVID-19 vaccine in reducing household transmission

Study examines clinical outcomes in vaccinated individuals hospitalized with SARS-CoV-2 Delta variant

Study reports on COVID-19 vaccine uptake and antibody prevalence in England during May 2021

Study suggests COVID-19 vaccine confidence and hesitancy in the UK driven by trust, not misinformation

COVID-19 vaccination in New York City reduces hospital admissions and deaths

NIH grant supports WVU-led team to increase COVID-19 testing among underserved populations

Owlstone Medical publishes data on the use of face mask filters to capture viral particles for SARS-CoV-2 detection

Yeast expressed, RBD-based vaccine provides robust immune responses against SARS-CoV-2

Redhill Biopharma announces completion of Phase 2/3 COVID-19 study of oral opaganib

How SARS-CoV-2 infects the brain

Exhausted T cells linked to increased risk of COVID-19 mortality

Study proves effectiveness of Artemisia annua against SARS-CoV-2 in vitro

Past SARS-CoV-2 infection enhances mRNA vaccine-induced neutralization of variants of concern

Neutralizing antibodies persist against SARS-CoV-2 at least a year after infection

Iodine derivative kills SARS-CoV-2 within 90 sec

Researchers develop new tool to simulate the impact of SARS-CoV-2 strains and vaccines

Thai study looks at CoronaVac vaccine vs. natural immunity to SARS-COV-2 variants

Antibody levels remain high nine months after SARS-CoV-2 infection, study shows

Functional autoantibody in COVID-19 contributes to the 'firestorm' of blood clots and inflammation

New project receives NIHR funding to develop personalized rehabilitation program for long Covid patients

Decoding Cannabis: Differentiating Hemp and Marijuana

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Latest News